Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine, University of California, San Francisco, San Francisco, CA 94143-0130, USA.
Crit Care Clin. 2012 Jul;28(3):363-72, v. doi: 10.1016/j.ccc.2012.04.001.
Transfusion-related acute lung injury (TRALI) is the leading cause of transfusion-related mortality. TRALI presents as acute lung injury (ALI) within 6 hours after blood product transfusion. Diagnosing TRALI requires a high index of suspicion, and the exclusion of circulatory overload or other causes of ALI. The pathophysiology of TRALI is incompletely understood, but in part involves transfusion of certain anti-neutrophil antibodies, anti-HLA antibodies, or other bioactive substances, into susceptible recipients. Recent studies have identified both recipient and transfusion risk factors for the development of TRALI. This article describes these TRALI risk factors, as well as diagnosis, treatment and prevention strategies.
输血相关性急性肺损伤（TRALI）是输血相关死亡的主要原因。TRALI 在输血后 6 小时内表现为急性肺损伤（ALI）。诊断 TRALI 需要高度怀疑，并排除循环超负荷或其他 ALI 的原因。TRALI 的病理生理学尚不完全清楚，但部分涉及输注某些抗中性粒细胞抗体、抗 HLA 抗体或其他生物活性物质到易感受者。最近的研究已经确定了 TRALI 的发生的受者和输血危险因素。本文描述了这些 TRALI 危险因素，以及诊断、治疗和预防策略。
